Key Highlights

  • EBR implanted 40 commercial WiSE systems in the September 2026 quarter, bringing total commercial implants to 157.
  • Medicare inpatient reimbursement for eligible WiSE procedures increased from 1 October 2026.
  • The company raised A$150 million and held cash and marketable securities of A$137.4 million at 30 September 2026.
  • A proposed National Coverage Determination decision from CMS is expected in early December 2026.

EBR Systems, Inc. (ASX:EBR), a developer of a wireless cardiac pacing device for heart failure, has released its quarterly activity report and Form 10-Q for the quarter ended 30 September 2026. The update, dated 10 November 2026, covers commercial implant activity in the United States, a reorganisation of the sales team, reimbursement changes, Manufacturing certification and regulatory steps. Commercial implant volumes were below management's expectations, particularly in September, and the company has highlighted this as the key operating issue for the coming quarter.

Commercial Implant Activity and Sales Reorganisation

The company implanted the WiSE system in 40 commercial patients during the quarter, taking total commercial implants across the pilot launch phase and limited market release to 157. Monthly cases in September were roughly half the average recorded in July and August. During the quarter EBR began restructuring its U.S. commercial organisation, following the departure of its chief commercial officer. The president and chief executive has taken direct responsibility for the commercial organisation while the company recruits a replacement.

The company reports that it has signed five additional purchasing contracts in the quarter, bringing the total to 57, and that 100 physicians have now been trained to implant the system, including 10 in the quarter. These figures show growth in access and training, but the company acknowledges that converting trained physicians and activated accounts into consistent procedure volumes remains the main challenge.

Reimbursement and Coverage Developments

The U.S. Centers for Medicare and Medicaid Services finalised higher inpatient payments for eligible WiSE procedures under its FY2027 inpatient payment rule, effective 1 October 2026. Eligible procedures were reassigned to higher-value diagnosis-related groups, increasing base payment rates by approximately 58 and 93 per cent for the relevant categories. The company says the new technology add-on payment may bring total Medicare reimbursement to between roughly US$67,000 and US$78,000, although actual payments depend on hospital and case-specific factors.

A proposed national coverage determination from CMS is expected in early December 2026, with a final decision to follow. A coverage decision would affect the scope of Medicare coverage for the device, and the timing and outcome remain outside the company's control.

Manufacturing, Regulatory and Safety Matters

The company's new Santa Clara Facility achieved ISO 13485 certification during the quarter, and the expanded site is expected to have capacity to manufacture up to 9,600 WiSE systems a year once fully operational. The U.S. Food and Drug Administration completed its pre-approval inspection in connection with a supplement to add the site as a manufacturing location. The inspection identified two observations, which the company has committed to correct. EBR continues to expect approval of the new site by the end of 2026, subject to FDA review.

The company also disclosed that it has been engaging with the FDA on a previously reported Cybersecurity incident and an echo-induced pacing risk. The FDA agreed that no immediate field corrective action or recall was warranted following its cybersecurity review. EBR plans to submit a supplement in the fourth quarter to increase the visibility of the pacing risk and its mitigations in the device labelling.

Funding, Cash Position and Risks

EBR completed a A$150 million Capital raising to fund commercial operations and manufacturing scale-up. At 30 September 2026 the company held cash, restricted cash and marketable securities of US$95.8 million, or about A$137.4 million. The company says it is focused on financial discipline, but ongoing commercial Investment means the cash balance will continue to be drawn down until implant volumes rise.

The risks are substantial and visible in the report. Implant volumes have been lower than expected, commercial Leadership has changed, and the coverage decision and pending manufacturing approval are both subject to regulatory timing. The cybersecurity matter and the labelling update add to the regulatory agenda.

Final Word

EBR's quarter combined reimbursement and manufacturing progress with lower implant activity and a commercial reset. The higher Medicare payments and the proposed coverage decision could support physician and hospital adoption, but only if the company converts its trained physicians and purchasing contracts into regular procedures. The next indicators will be the December coverage decision, the FDA decision on the new manufacturing site and the implant numbers reported for the December quarter.